Recent updates from the MONALEESA‐2, ‐3, and ‐7 trials demonstrated statistically significant PFS and OS benefits for ribociclib in combination with endocrine therapy in HR‐positive, HER2‐negative advanced breast cancer [70, 71, 72]. The gene discussed is ERBB2; the disease is breast carcinoma.